New York, Jan 7, 2026, 05:35 ET — Premarket
- ALGN closed up 4.7% on Tuesday at $167.66, its second straight gain.
- Align set Feb. 4 for fourth-quarter and full-year 2025 results after the market close.
- Investors are watching demand signals for clear aligners and digital dentistry tools.
Align Technology shares rose 4.7% on Tuesday to close at $167.66, a second straight gain in a broader market advance. The Invisalign maker remains about 29% below its 52-week high and lagged Dentsply Sirona’s 6.6% jump, though it beat Zimmer Biomet; about 1.2 million shares changed hands. 1
The next clear catalyst is Feb. 4, when Align said it will report fourth-quarter and full-year 2025 results after the close, with the release due at 4 p.m. ET and a conference call at 4:30 p.m. ET. It also flagged expected earnings-release dates for 2026: April 29, July 29, Oct. 28 and Feb. 3, 2027. 2
That matters because investors still treat demand for orthodontic work as a litmus test for consumer spending on elective care. When Align cut its 2025 revenue-growth forecast last July, Chief Executive Joe Hogan cited “less overall patient traffic” and “patient hesitation toward elective procedures” in a statement, pointing to a softer backdrop for clear aligners and scanner sales. 3
Align’s tone improved later in the year. In late October, the company beat third-quarter estimates and raised its fourth-quarter revenue forecast to $1.03 billion to $1.05 billion; Hogan said the results showed “year-over-year growth in Clear Aligner volumes,” meaning Invisalign case shipments, even as the company booked $88.3 million in restructuring-related charges. 4
A Zacks Investment Research report dated Jan. 6 kept a “Neutral” long-term recommendation and set a 6–12 month price target of $168. Zacks’ consensus estimates put fourth-quarter revenue at about $1.03 billion and earnings at about $2.27 per share, while flagging foreign-exchange swings and competition as key pressures to watch. 5
But the stock’s path into earnings is not one-way. If dentists see fewer “case starts” — new patients beginning treatment — or if Align leans harder on discounting to defend share, margins can tighten quickly.
